NHS National Pharmaceuticals Transition 2021_2 - Pemetrexed LSNE

NHS National Pharmaceuticals Transition 2021_2 - Pemetrexed LSNE:

Offer reference number: CM/PHG/21/5639/00

Period of framework agreement: The total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months)

FIND A TENDER (FTS) Reference number: 2021/S 000-008845

Potential periods of call-offs under the framework agreement:

24/06/2021 to 31/01/2023 (19 months) LSNE region.

Tender Documents

• Opportunity notice on Contracts Finder → — Tender notice
• Document No. 05a (ii) CM_PHG_21_5639_00 SELECTT Application → — Link
• Document No. 08 - Confidential information schedule → — Link
• Document No. 01 - Invitation to offer covering letter → — Link
• Document No. 06 - Form of offer → — Link
• Document No. 05a (i) Product Listing and Usage - Transition (CM_PHG_21_5639_00) → — Link
• Document No. 09 - Stability Data Requirements → — Link
• Qualification Questionnaire - Transition 2021_2 - Pemetrexed Solution for Infusion LSNE → — Link
• Document No. 07b - Guidance for performing a risk assessment of licensed medicines for the NHS → — Link
• Document No. 03 - Framework Agreement and Terms and Conditions → — Link
• Document No. 02 - Terms of Offer → — Link
• Document No. 07a - Quality control technical sheet → — Link
• Document No. 05b - Selectt offer schedule instructions → — Link
• Document No. 04 - Contract technical specification → — Link